Matrix Laboratories says gets WHO approval for HIV durg
MUMBAI (Reuters) - Matrix Laboratories Ltd said it got approval from the World Health Organisation (WHO) for generic version of a drug to treat the human immuno-deficiency virus (HIV).
The WHO approval enables Matrix to market Lopinavir or Ritonavir tablets in dosages of 200 mg or 50 mg in most countries outside the United States and Europe, the company said in a statement on Thursday.
The tablets are the generic version of Abott Laboratories' Kaltera tablets, it added.
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India during the Reuters India Investment Summit in Mumbai and Bangalore. Full Coverage | Blog
PLAYBOY SALE
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article
India
US
UK
